Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2731294-23-6
2. 54py2pbn7s
3. 1-(4-(4-amino-7-cyclopropylpyrrolo(2,3-d)pyrimidin-5-yl)-2-fluorophenyl)-3-(5-(1-(trifluoromethyl)cyclopropyl)-1,2-oxazol-3-yl)urea
4. 1-[4-(4-amino-7-cyclopropylpyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-3-[5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-yl]urea
5. Refchem:1093845
6. Ofirnoflastum
7. Ofirnoflast [inn]
8. Ofirnolast [usan]
9. Ofirnoflast (usan/inn)
10. Orb2802265
11. Schembl23966707
12. Schembl29484521
13. Gtpl13227
14. Bdbm522987
15. Us11161852, Compound 10
16. Ex-a10121
17. Ht-6184
18. Example 10 [wo2021242505]
19. Hy-159520
20. D13076
21. 1-(4-(4-amino-7- Cyclopropyl-7h- Pyrrolo[2,3- D]pyrimidin-5-yl)-2- Fluorophenyl)-3-(5-(1- (trifluoromethyl)cyclopropyl)isoxazol- 3-yl)urea
22. N-[4-(4-amino-7-cyclopropyl-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-n'-[5-[1-(trifluoromethyl)cyclopropyl]-3-isoxazolyl]urea
23. N-[4-(4-amino-7-cyclopropyl-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-n'-{5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-yl}urea
24. Urea, N-(4-(4-amino-7-cyclopropyl-7h-pyrrolo(2,3-d)pyrimidin-5-yl)-2-fluorophenyl)-n'-(5-(1-(trifluoromethyl)cyclopropyl)-3-isoxazolyl)-
| Molecular Weight | 501.4 g/mol |
|---|---|
| Molecular Formula | C23H19F4N7O2 |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 5 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 124 |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 842 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
83
PharmaCompass offers a list of Ofirnoflast API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ofirnoflast manufacturer or Ofirnoflast supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ofirnoflast manufacturer or Ofirnoflast supplier.
A Ofirnoflast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ofirnoflast, including repackagers and relabelers. The FDA regulates Ofirnoflast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ofirnoflast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ofirnoflast supplier is an individual or a company that provides Ofirnoflast active pharmaceutical ingredient (API) or Ofirnoflast finished formulations upon request. The Ofirnoflast suppliers may include Ofirnoflast API manufacturers, exporters, distributors and traders.
Ofirnoflast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ofirnoflast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ofirnoflast GMP manufacturer or Ofirnoflast GMP API supplier for your needs.
A Ofirnoflast CoA (Certificate of Analysis) is a formal document that attests to Ofirnoflast's compliance with Ofirnoflast specifications and serves as a tool for batch-level quality control.
Ofirnoflast CoA mostly includes findings from lab analyses of a specific batch. For each Ofirnoflast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ofirnoflast may be tested according to a variety of international standards, such as European Pharmacopoeia (Ofirnoflast EP), Ofirnoflast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ofirnoflast USP).
